Ascelia Pharma presentation at Redeye Investor Forum

Ascelia Pharma is reporting on 4/11. Below is a summary of the presentation at Redye Research.

Ascelia sold off after Q2 based on slower recruitment of patients for Phase 3 study of Orviglance due to Covid restrictions. The bar is very low. Positive Q3 patients recruitment data on Thursday could drive the stock up materially.

Ascelia has two products:


  • A contrast agent for kidney MRI. Currently in advanced Phase 3 study.
  • Target market of UDS 500-600 million of annually
  • 6 studies for Phase 1 and 2 completed
  • Pivotal Phase 3 study in 50 sites is due to be completed in 1H22 – including Mayo and Karolinske


  • oral drug for treating gastric cancer
  • Better efficacy and safety
  • Phase 2 study due to be completed in 2024
  • Clinical collaboration on Oncolar with Taiho Oncology
  • After gastric is planning

Watch the full presentation from the Redeye conference:

Ascelia Pharma is fully funded to complete the above studies.

We are long Ascelia Pharma.

Enter your email address to subscribe to this blog and receive notifications of new posts by email.


The goal of the blog is to provide investment ideas for further research. I/we have a beneficial position in the shares discussed above either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. The article does not represent investment advice.

Leave a Comment

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s